Recent Updates on mRNA Vaccines

Emily Sydow 1, Abu Salim Mustafa 2, Asma Hanif 3, Javed Tunio 4, Shumaila Nida Muhammad Hanif 1

Affiliations

doi: 10.3390/vaccines10081209

Abstract

Messenger RNA has been studied by everyone, from vaccine developers to high school biology students, since the discovery of its isolation in 1961 [...].

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Maruggi G, Zhang C, Li J, Ulmer JB, Yu D.Mol Ther. 2019 Apr 10;27(4):757-772. doi: 10.1016/j.ymthe.2019.01.020. Epub 2019 Feb 7.PMID: 30803823 Free PMC article. Review.

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview.

Machado BAS, Hodel KVS, Fonseca LMDS, Mascarenhas LAB, Andrade LPCDS, Rocha VPC, Soares MBP, Berglund P, Duthie MS, Reed SG, Badaró R.Vaccines (Basel). 2021 Nov 17;9(11):1345. doi: 10.3390/vaccines9111345.PMID: 34835276 Free PMC article. Review.

The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.

Ladak RJ, He AJ, Huang YH, Ding Y.Front Immunol. 2022 May 6;13:885371. doi: 10.3389/fimmu.2022.885371. eCollection 2022.PMID: 35603213 Free PMC article. Review.

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.

Rouf NZ, Biswas S, Tarannum N, Oishee LM, Muna MM.RNA Biol. 2022;19(1):386-410. doi: 10.1080/15476286.2022.2055923. Epub 2021 Dec 31.PMID: 35354425 Free PMC article. Review.

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Chakraborty C, Sharma AR, Bhattacharya M, Lee SS.Front Immunol. 2021 Jul 7;12:679344. doi: 10.3389/fimmu.2021.679344. eCollection 2021.PMID: 34305909 Free PMC article. Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Brenner S., Jacob F., Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature. 1961;190:576–581. doi: 10.1038/190576a0. - DOI - PubMed
  2.  
    1. Gros F., Hiatt H., Gilbert W., Kurland C.G., Risebrough R.W., Watson J.D. Unstable ribonucleic acid revealed by pulse labeling of Escherichia coli. Nature. 1961;190:581–585. doi: 10.1038/190581a0. - DOI - PubMed
  3.  
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
  4.  
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. - DOI - PMC - PubMed
  5.  
    1. Jackson L.A., Roberts P.C., Graham B.S. A SARS-CoV-2 mRNA vaccine-Preliminary report. Reply. N. Engl. J. Med. 2020;383:1191–1192. doi: 10.1056/NEJMoa2022483. - DOI - PubMed
  6.  
    1. Rauch S., Gooch K.E., Hall Y., Salguero F.J., Dennis M.J., Gleeson F.V., Harris D.J., Ho C.M., Humphries H.E., Longet S., et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv. 2020:12.23.424138. doi: 10.1101/2020.12.23.424138. - DOI
  7.  
    1. Kremsner P., Mann P., Oostvogels L., Kreidenweiss A., Leroux-Roels I., Leroux-Roels G., Kroidl A., Schunk M., Schindler C., Fendel R., et al. Phase 1 Assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. medRxiv. 2020:11.09.20228551. doi: 10.1101/2020.11.09.20228551. - DOI
  8.  
    1. Dror A.A., Eisenbach N., Taiber S., Morozov N.G., Mizrachi M., Zigron A., Sela E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020;35:775–779. doi: 10.1007/s10654-020-00671-y. - DOI - PMC - PubMed
  9.  
    1. Wang H.-B., Mo Q.-H., Yang Z. HIV Vaccine Research: The Challenge and the Way Forward. J. Immunol. Res. 2015;2015:503978. doi: 10.1155/2015/503978. - DOI - PMC - PubMed
  10.  
    1. A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) [(accessed on 18 June 2022)]; Available online: https://clinicaltrials.gov/ct2/show/NCT05001373.
  11.  
    1. Venkatesan P. Preliminary phase 1 results from an HIV vaccine candidate trial. Lancet Microbe. 2021;2:e95. doi: 10.1016/S2666-5247(21)00042-2. - DOI - PubMed
  12.  
    1. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., Benjamin R., Lu D., Curiel D.T. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55:1397–1400. - PubMed
  13.  
    1. Kallen K.J., Heidenreich R., Schnee M., Petsch B., Schlake T., Thess A., Baumhof P., Scheel B., Koch S.D., Fotin-Mleczek M. A novel, disruptive vaccination technology: Self-adjuvanted RNActive vaccines. Hum. Vaccin. Immunother. 2013;9:2263–2276. doi: 10.4161/hv.25181. - DOI - PMC - PubMed
  14.  
    1. Cleve M. What the lightning-fast quest for COVID vaccines means for other diseases. Nature. 2021;589:16–18. - PubMed
  15.  
    1. Rutkowski K., Mirakian R., Till S., Rutkowski R., Wagner A. Adverse reactions to COVID-19 vaccines: A practical approach. Clin. Exp. Allergy. 2021;51:770–777. doi: 10.1111/cea.13880. - DOI - PMC - PubMed
  16.  
    1. Niebel D., Novak N., Wilhelmi J., Ziob J., Wilsmann-Theis D., Bieber T., Braegelmann C. Cutaneous adverse reactions to COVID-19 vaccines: Insights from an immuno-dermatological perspective. Vaccines. 2021;9:944. doi: 10.3390/vaccines9090944. - DOI - PMC - PubMed
  17.  
    1. Samarakoon U., Alvarez-Arango S., Blumenthal K.G. Delayed Large Local Reactions to mRNA COVID-19Vaccines in Blacks, Indigenous Persons, and People of Color. N. Engl. J. Med. 2021;385:662–664. doi: 10.1056/NEJMc2108620. - DOI - PMC - PubMed
  18.  
    1. McMahon D.E., Amerson E., Rosenbach M., Lipoff J.B., Moustafa D., Tyagi A., Desai S.R., French L.E., Lim H.W., Thiers B.H., et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J. Am. Acad. Dermatol. 2021;85:46–55. doi: 10.1016/j.jaad.2021.03.092. - DOI - PMC - PubMed
  19.  
    1. Wei N., Fishman M., Wattenberg D., Gordon M., Lebwohl M. “COVID arm”: A reaction to the Moderna vaccine. JAAD Case Rep. 2021;10:92–95. doi: 10.1016/j.jdcr.2021.02.014. - DOI - PMC - PubMed
  20.  
    1. Zhang C., Maruggi G., Shan H., Li J. Advances in mRNA vaccines for infectious diseases. Front. Immunol. 2019;10:594. doi: 10.3389/fimmu.2019.00594. - DOI - PMC - PubMed
  21.  
    1. Kowalzik F., Schreiner D., Jensen C., Teschner D., Gehring S., Zepp F. mRNA-based vaccines. Vaccines. 2021;9:390. doi: 10.3390/vaccines9040390. - DOI - PMC - PubMed

Page Navigation